|
Sep 5
|
REFILE-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Sep 5
|
Beat the Market the Zacks Way: NVIDIA, Novo Nordisk, Matson in Focus
|
|
Sep 5
|
UPDATE 1-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Sep 5
|
Wegovy maker Novo Nordisk leapfrogs LVMH to become Europe’s most valuable company after it takes its ‘miracle’ weight loss drug to the U.K.
|
|
Sep 5
|
20 Most Addictive Foods According to Science
|
|
Sep 5
|
Trending tickers: Apple l Microsoft l Novo Nordisk l Ashtead
|
|
Sep 5
|
Novo Nordisk Is Now Europe’s Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.
|
|
Sep 5
|
UPDATE 6-Wegovy reaches Britain as NHS, private outlets receive weight loss drug
|
|
Sep 5
|
FTSE and Wall Street lower as pound slides and US factory orders plunge
|
|
Sep 5
|
The ‘miracle’ weight loss drug causing euphoria and fear in Scandinavia
|
|
Sep 5
|
RPT-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Sep 5
|
MORNING BID EUROPE-China optimism dissipates after weak data
|
|
Sep 4
|
CORRECTED (OFFICIAL)-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Sep 4
|
Weight-loss drug maker Novo Nordisk becomes Europe’s most valuable company
|
|
Sep 4
|
UPDATE 4-Wegovy makes UK weight-loss debut even as Novo struggles with supplies
|
|
Sep 4
|
UPDATE 1-Wegovy weight-loss drug will cost 199-299 pounds for private UK patients -Simple Online Pharmacy
|
|
Aug 29
|
Eli Lilly and Other Pharma Stocks Are Ignoring Medicare’s 10 Drug List
|
|
Aug 29
|
Shares of Wegovy Partner Catalent Jump After Striking Deal With Activist Investor Elliott
|
|
Aug 29
|
Biden admin unveils ten drugs picked for Medicare price negotiations
|
|
Aug 29
|
Does the Red-Hot Weight-Loss Market Make This Pharmaceutical Stock a Buy?
|